^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Pancreatic Adenocarcinoma

    Related cancers:
    21h
    Carolyn-USA: A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer (clinicaltrials.gov)
    P1/2, N=144, Recruiting, Engeneic Pty Limited | Not yet recruiting --> Recruiting
    Enrollment open
    |
    EGFR (Epidermal growth factor receptor)
    |
    EGFR expression
    |
    gemcitabine • albumin-bound paclitaxel
    1d
    Nimotuzumab Combined With Chemoradiotherapy in the Treatment of Unresectable Locally Advanced or Oligometastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=30, Enrolling by invitation, Peking University First Hospital
    New P2 trial
    |
    capecitabine • TheraCIM (nimotuzumab)
    2d
    Gemcitabine Hydrochloride, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Metformin Hydrochloride, and a Standardized Dietary Supplement in Treating Patients With Pancreatic Cancer That Cannot be Removed by Surgery (clinicaltrials.gov)
    P1, N=21, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jan 2026 --> Dec 2026
    Trial completion date
    |
    gemcitabine • albumin-bound paclitaxel • metformin
    2d
    Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. (PubMed, Eur J Cancer)
    Patient- and tumour-specific characteristics strongly influence survival in mPAC patients receiving systemic therapy. These findings can support a more detailed risk stratification at diagnosis to optimise treatment selection, avoid both over- and undertreatment, and align care with individual patient expectations and values for more personalised treatment strategies.
    Journal
    |
    CA 19-9 (Cancer antigen 19-9)
    |
    LDH elevation
    |
    5-fluorouracil • irinotecan • leucovorin calcium
    4d
    NT-175-201: A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation (clinicaltrials.gov)
    P1, N=46, Recruiting, AstraZeneca | N=162 --> 46 | Trial completion date: Aug 2039 --> Jul 2029
    Enrollment change • Trial completion date
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    cyclophosphamide • fludarabine IV • NT-175
    5d
    CAR T Cell Immunotherapy for Pancreatic Cancer (clinicaltrials.gov)
    P1, N=54, Terminated, University of Pennsylvania | N=18 --> 54 | Trial completion date: Dec 2025 --> Feb 2025 | Active, not recruiting --> Terminated | Trial primary completion date: Dec 2025 --> Feb 2025; Administrative reasons
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    5d
    Clinical Trial of OMTX705 in Combination With Gemcitabine/Nab-Paclitaxel and Tislelizumab in Patients With Advanced/Metastatic Pancreatic Adenocarcinoma (clinicaltrials.gov)
    P1, N=69, Recruiting, Oncomatryx Biopharma S.L.
    New P1 trial
    |
    KRAS (KRAS proto-oncogene GTPase) • CA 19-9 (Cancer antigen 19-9)
    |
    gemcitabine • Tevimbra (tislelizumab-jsgr) • albumin-bound paclitaxel • OMTX705
    6d
    Research on Disease-Specific Exosome Detection Technologies and Prototype Development (Common Key Technologies) (ChiCTR2600116298)
    P=N/A, N=0, Not yet recruiting, Southern Medical University Southern Hospital; Southern Medical University Southern Hospital
    New trial
    6d
    Clinical application of FL-091 radionuclide imaging in diagnosis and staging of malignant tumors (ChiCTR2500113089)
    P=N/A, N=0, Recruiting, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University o
    New trial
    6d
    Nimotuzumab Combined With Nab-paclitaxel/Gemcitabine in the Perioperative Treatment of High-risk Resectable/Borderline Resectable Pancreatic Cancer (ChiCTR2500114031)
    P2, N=156, Not yet recruiting, Peking University Cancer Hospital & Institute; Peking University Cancer Hospital & Institute
    New P2 trial
    |
    KRAS (KRAS proto-oncogene GTPase)
    |
    gemcitabine • albumin-bound paclitaxel • TheraCIM (nimotuzumab)